Kura Oncology (NASDAQ:KURA) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Kura Oncology (NASDAQ:KURA) in a research note released on Thursday, MarketBeat Ratings reports. The firm issued an overweight rating and a $30.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, August 24th. CLSA set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Morgan Stanley set a $24.00 price target on Kura Oncology in a research report on Monday, August 24th. Finally, Wedbush boosted their price target on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $25.69.

Kura Oncology Stock Performance

Shares of KURA stock opened at $10.65 on Thursday. The firm has a market cap of $947.42 million, a price-to-earnings ratio of -3.16 and a beta of 0.47. Kura Oncology has a 52-week low of $7.36 and a 52-week high of $13.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The company’s 50 day moving average is $11.23 and its 200 day moving average is $10.19.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. On average, sell-side analysts anticipate that Kura Oncology will post -3.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, insider Brian Powl sold 17,020 shares of Kura Oncology stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.53, for a total transaction of $179,220.60. Following the sale, the insider owned 152,249 shares of the company’s stock, valued at $1,603,181.97. The trade was a 10.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Francis Burrows sold 20,726 shares of the business’s stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $10.83, for a total transaction of $224,462.58. Following the transaction, the insider owned 42,327 shares in the company, valued at $458,401.41. The trade was a 32.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 153,881 shares of company stock worth $1,708,183 in the last ninety days. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Kura Oncology in the second quarter valued at approximately $115,286,000. Armistice Capital LLC lifted its holdings in Kura Oncology by 5.7% during the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after buying an additional 264,000 shares in the last quarter. Bank of America Corp DE purchased a new position in Kura Oncology in the 2nd quarter valued at approximately $12,735,000. Dimensional Fund Advisors LP grew its stake in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after acquiring an additional 348,127 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Kura Oncology in the second quarter worth $10,927,000.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: JPMorgan initiated coverage with an Overweight rating and a $30 price target, implying roughly 182% upside from the referenced share price. The rating reflects confidence in Kura’s precision-oncology pipeline and could improve investor awareness and institutional interest. JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target This biotech making precision medicines for cancer could nearly triple, says JPMorgan
• Positive Sentiment: Additional analyst coverage highlighting Kura Oncology and AbbVie may increase visibility for the company among healthcare investors. Analysts Offer Insights on Healthcare Companies: Kura Oncology and AbbVie
• Neutral Sentiment: Kura granted inducement stock options covering 128,250 shares to nine new employees. The awards support hiring and execution but could create modest future dilution; the options were issued under the Nasdaq employment-exception rules. Kura Oncology Reports Inducement Grants
• Negative Sentiment: Several insiders, including CMO Mollie Leoni, Brian Powl, Kathleen Ford, Thomas James Doyle and Teresa Brophy Bair, reported selling shares. These transactions may weigh on sentiment, although some sales followed PSU vesting and may reflect routine compensation-related selling rather than reduced confidence.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth.

Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway.

Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions.